Effect of dapagliflozin on the triglyceride-glucose index and the atherogenic index of plasma used as markers of atherosclerosis in patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Effect of dapagliflozin on the triglyceride-glucose index and the atherogenic index of plasma used as markers of atherosclerosis in patients with type 2 diabetes mellitus

Published:2023-09-11 Issue: Volume: Page:
ISSN:0973-3930
Container-title:International Journal of Diabetes in Developing Countries
language:en
Short-container-title:Int J Diabetes Dev Ctries

Author:

Gezer Deniz^ORCID,Öztürk Semra Özkan^ORCID,Kocaman Zehra^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://link.springer.com/content/pdf/10.1007/s13410-023-01246-9.pdf

Reference22 articles.

1. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49. https://doi.org/10.1016/j.diabres.2013.11.002.

2. Rao Kondapally Seshasai S, Kaptoge S, Thompson A et al; Emerging Risk Factors Collaboration. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364(9):829-841. https://doi.org/10.1056/NEJMoa1008862. Erratum in: N Engl J Med. 2011 Mar 31;364(13):1281.

3. Wu QL, Zheng T, Li SZ, et al. Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2022;14:41. https://doi.org/10.1186/s13098-022-00810-3.

4. Briand F, Mayoux E, Brousseau E, Burr N, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65(7):2032–8. https://doi.org/10.2337/db16-0049.

5. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.